Emerging Company Showcase Presentations

ECS01 – deepeye Medical

Seeing More, In Less Time. deepeye® TPS is the world’s first AI assistant for predictive retinal Therapy Planning Support and automated documentation.

deepeye Medical GmbH (DPY) is a heathtech company headquartered in Munich and provides clinicians with an AI assistant for retinal therapies. Our mission is to empower ophthalmologists to see more clinical detail while spending less time on manual analysis and documentation. Our flagship solution, deepeye® TPS (Therapy Planning Support), acts like an “AI-voice-scribe” – but for imaging, transforming complex OCT histories into actionable, one-glance clinical insights.

Seeing More: Clinical Depth & Predictive Power

Beyond Segmentation: While traditional OCT AI focuses on biomarkers, deepeye® TPS provides a disease activity assessment and a comprehensive 12-month therapy response prognosis for anti-VEGF. This allows clinicians to move from reactive to proactive care, answering the patient’s most vital question: “What is my personal therapy outlook?”
Objective Trend Analysis: The system “reads” the OCTs of the last 1-2 years to visualize disease activity progression for therapy success as well as changes to a treatment need prognosis. By identifying subtle “Good vs. Bad Responder” patterns, it goes beyond biomarkers with its traffic-light charts. It has shown to positively influence therapy decisions (e.g. earlier interval shorterning) and thus can support clinicians in keeping patients on the optimal to stable vision.
The “deepeye Effect”: By providing objective data for interval planning, the system supports physicians in evidence-led patient retention and might improve long-term visual stabilization, compared to traditional real-world outcomes.

In Less Time: Unmatched Operational Efficiency

3x Faster Review: deepeye® TPS delivers up to 60% time saving per OCT analysis and documentation. For high-volume clinics, this translates to gaining up to one hour of surgery time every day, enabling less stress & manageable workloads for the team and increasing patient throughput.
90% Less Typing: The AI analysis automatically provides a standardized text summaries for EMRs. This can drastically reduce the burden of manual documentation, ensuring standardized OCT analysis records for quality assurance by payors with minimal effort.
Seamless Workflow: DPY is device-agnostic (Topcon, Zeiss, Heidelberg, Optopol …) and works with all major image management platforms (Heyex, FORUM, Harmony etc.) as well as EMRs.

Key Outcome Goals

Clinical Excellence: Need-based therapy planning through predictive, data-driven interval planning and efficient & effective patient education.
Human-in-the-Loop Safety: Enhanced therapy decision confidence thanks to assistive AI (that does not replace a doctor’s decision!), fulfilling the requirements of the EU AI Act and ophthalmic ethical AI guidelines (BVA/DOG/EURETINA).
Economic Sustainability: Boost practice ROI by increasing efficiency and reducing possible risks, e.g. incomplete documentation, incorrect billing and quality assurance findings by payors.

Company website: https://www.deepeye-medical.com/

Supporting documents

Get in touch

ECS02 – Lightfield Medical

Lightfield Medical: Solving ophthalmology’s missing link — autonomous slit-lamp imaging that technicians can capture and doctors can trust

The slit lamp has anchored anterior segment examination for nearly a century, yet the exam remains ephemeral — visible only to the clinician present, gone when the patient leaves. Demand for ophthalmic care is projected to rise 24% by 2035 while the ophthalmologist workforce shrinks. The only solution is delegation, and delegation requires a device that a technician can operate without specialized skill. That device has not existed — until now.

Conventional slit lamp cameras require a skilled operator and produce unstandardized images across nine independent degrees of freedom. Nothing is comparable across visits, and meaningful technician delegation is not possible.

Lightfield Medical designed Captura from first principles. A dual tunable liquid lens system autofocuses the full anterior segment automatically. A programmable digital light engine generates any illumination pattern on demand. A non-parfocal optical design captures the complete exam with a single moving component. A technician presses one button and a standardized, navigable digital record is produced in seconds.

The programmable illumination unlocks imaging impossible on a conventional slit lamp. Compound slits combine two illumination types in one frame, cutting acquisition time and storage costs by half. A miniaturized slit prism with 780nm illumination produces the world’s first full-pupil retroillumination image — no white bar artifact, no dilation — enabling routine technician screening for Fuchs’ dystrophy, ABMD, and cataract. Annular sclerotic scatter, in development, will be the first of many further novel modalities the platform is expected to unlock.

The Captura Viewer iOS app lets a reviewing physician navigate the captured exam by gesture from any location. Routine follow-up visits can be handled by technicians at remote sites with asynchronous physician review. One physician can cover multiple retail optical locations remotely — a critical capability given that roughly half of Americans currently skip their recommended annual eye exam due to a shortage of on-site optometrists.

Because every Captura image is captured under identical software-defined conditions, the dataset is reproducible across every device in the field — the prerequisite for reliable AI training.

Lightfield Medical operates on a DaaS subscription model across a global market of more than 80,000 ophthalmology practices. The company holds granted patents in the US and Europe with prosecution underway in eight additional jurisdictions — hundreds of claims covering the core technology and designed to block competitive workarounds. The strategic path targets acquisition by a major ophthalmic platform, and conversations with relevant parties are underway.

Company website: www.lightfieldmedical.com

Supporting documents

Get in touch

ECS03 – PulseMedica

PulseMedica SVO-Tx Image-Guided Femtosecond Laser System

PulseMedica is pioneering ophthalmic laser surgery with the world’s first image-guided femtosecond laser platform designed to image, diagnose, and treat vitreoretinal disease. Our lead clinical application targets vitreous opacities, or eye floaters, which represent a major unmet need in ophthalmology and are one of the most common patient complaints. This includes post-PVD and post-cataract patients who remain symptomatic despite otherwise successful eye care, and who cannot access, are not candidates for, or do not want vitrectomy or off-label YAG vitreolysis.

Over 50% of adults experience floaters, and 10-25% suffer moderate-to-severe visual impairment and distraction affecting daily function. Imaging and treating floaters is technologically difficult because floaters are small, mobile, translucent collagen-based structures within the vitreous, requiring objective imaging, real-time tracking, treatment planning, and precise laser delivery near sensitive anatomy.

The dominant approach is “wait and see,” which leaves symptomatic patients without meaningful treatment. Vitrectomy can remove floaters but is invasive and carries risks such as retinal tears, endophthalmitis, and early-onset cataract formation. Off-label YAG vitreolysis is manual, imprecise, not FDA-approved for floater treatment, and lacks consistent effectiveness and purpose-built safety features. Current care also lacks objective diagnostic tools, treatment planning capabilities, and a standardized referral pathway.

PulseMedica’s platform system solves these shortcomings by integrating imaging, planning, and treatment delivery into one physician-supervised workflow. The system combines OCT/SLO imaging, a patient docking interface for eye stabilization, AI-based floater tracking, automated treatment volume execution, and femtosecond laser photoionization. Unlike vitrectomy or off-label YAG vitreolysis, PulseMedica’s approach is purpose-built for floater imaging and treatment, non-invasive, and designed to reduce risk from human error and subjective judgment. By precisely delivering laser volumes while tracking floater motion and avoiding heat-based tissue disruption, the platform is designed to enable objective diagnosis and effective treatment through a fast, predictable, repeatable, office-based procedure.

Company website: www.pulsemedica.com

Supporting documents

Get in touch

ECS04 – Ophthalmology, HelpMeSee. Inc

Scaling Cataract Surgery Training Through High-Fidelity Simulation: The HelpMeSee Competency-Based Approach to Building Global Surgical Capacity

Cataract remains one of the world’s leading causes of preventable blindness, yet access to quality cataract surgery is limited in many regions by a shortage of trained surgeons and inconsistent opportunities for hands-on training. Traditional surgical education relies heavily on live patient exposure, variable case availability, mentor-dependent teaching, and gradual skill acquisition under high-pressure clinical conditions. These constraints can lengthen the learning curve and limit the ability to repeatedly practice critical steps or rare complications before entering the operating room.
HelpMeSee addresses this training bottleneck through a simulation-based surgical education system designed specifically for cataract care. Founded on principles adapted from aviation simulation, HelpMeSee combines high-fidelity virtual reality, haptic feedback that mimics tactile tissue interaction, structured curriculum, instructor-led training, and real-time objective performance feedback. This approach allows cataract specialists to practice essential procedural steps repeatedly in a risk-free environment.  It also builds hand-eye coordination, confidence and provides trainees standardized guidance before transitioning to live surgery.
The HelpMeSee training portfolio includes Manual Small Incision Cataract Surgery (MSICS) training, Phacoemulsification training, and supplementary modules covering complex or complication-focused scenarios such as Posterior Capsular rupture Management, Zonular Dialysis Management, Secondary IOL Techniques, Small Pupil Management, and Suturing. By enabling unlimited repetition, consistent instruction, measurable progress, and exposure to simulated complications, the system supports competency-based learning rather than relying solely on time-in-training or chance case exposure.

The HelpMeSee global model is designed for scalability through training centers, partner institutions, and locally integrated pathways. The organization’s mission is to restore vision to people living with severe visual impairment and blindness due to cataract worldwide, while its strategy focuses on innovative, scalable, technology-driven surgical simulation training. At ESCRS iNovation Day, HelpMeSee will present how simulation can help strengthen cataract surgical education and improve readiness for live surgery. This improves patient safety and supports the growth of sustainable surgical capacity, especially important in regions with the greatest need.

Company website: www.helpmesee.org

Supporting documents

Get in touch

ECS05 –  VisiRose, Inc.

Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT): A Resistance-Proof, Broad-Spectrum Treatment for Infectious Keratitis and Corneal Disease — Developed at Bascom Palmer Eye Institute

VisiRose, Inc.

VisiRose is a clinical-stage ophthalmic biotechnology company advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT), a non-invasive, light-activated treatment for infectious keratitis developed at Bascom Palmer Eye Institute, the #1-ranked U.S. eye hospital.

The Technology

RB-PDAT is a drug-device combination treatment that pairs rose bengal — a synthetic small molecule with 100+ years of safe ophthalmic use — with targeted green-light activation to destroy pathogens via reactive oxygen species. The mechanism is physical, not biological: no resistance has been documented across any pathogen class. The proprietary active pharmaceutical ingredient is manufactured under Current Good Manufacturing Practice using a Quality by Design synthesis process developed in accordance with International Council on Harmonisation guidelines to meet chemistry, manufacturing, and control regulatory requirements. One mechanism. Indifferent to pathogen class. Hard to resist.

The Market Opportunity

Infectious keratitis affects 5 to 10 million patients annually and is a leading cause of corneal blindness worldwide. When antimicrobials fail and drug-resistant bacterial, fungal, parasitic, and viral strains are making that increasingly likely, the fallback is corneal transplant surgery. RB-PDAT eliminates that fallback. The addressable global market for rose bengal-based ophthalmic therapies exceeds $20 billion, spanning antimicrobial resistance-concern markets in the U.S. and Europe, high-incidence markets across Asia, Latin America, and Africa, and adjacent ophthalmic indications enabled by the molecule’s intrinsic mechanisms.

The Evidence Base

36 peer-reviewed publications covering in vitro, in vivo, clinical, and mechanistic work; 280+ patients treated across six institutions in four countries on three continents. The REAGIR Phase 3 RCT (NCT05110001) — 330 patients, double-masked, sham-controlled — delivered the first positive signal against natamycin as standard of care in nearly 50 years: directionally favorable results in the Fusarium subgroup, the trial’s largest and most powered cohort.

Key Outcome Goals

Regulatory approval in the U.S., Europe, and key international markets for Fusarium fungal infectious keratitis. Protocol optimization informed by REAGIR subgroup findings. Indication expansion into infectious scleritis, corneal ectasia, keratoconus, and floppy eyelid syndrome. A scalable, low-cost delivery model deployable across academic and community ophthalmology settings globally.

RB-PDAT is a platform with the potential to redefine the standard of care for corneal infection — reducing preventable blindness, displacing costly surgery, and outpacing microbial resistance.

Company website: www.visirose.com

Supporting documents

Get in touch

ECS06 – Allotex

Allotex pioneers tissue-addition vision correction for presbyopia. By adding natural, sterile corneal collagen, it restores the eye’s range of vision while preserving optical quality and future treatment options—already commercially launched and advancing on the U.S. regulatory pathway.

Company non-confidential summary: The global “presbyopia gap” represents a large, underserved segment—approximately 30% of the population aged 40–60 with emmetropia or low ametropia—who want near vision restoration without sacrificing distance vision or committing to irreversible surgery.
Allotex addresses this high-value segment with a differentiated, biologic solution: a sterile, ethically sourced human collagen allograft, optically shaped with micron-level precision. This additive technology preserves corneal integrity and maintains all future treatment options—positioning it as a category-defining innovation. With accelerating commercial growth in Europe, Canada, and other regions, an active U.S. FDA clinical pathway, and a focused APAC expansion strategy, Allotex is building a scalable global platform and establishing Tissue Addition Technology as a new standard in refractive surgery.

Company website: eu.allotex.com/

Supporting documents

Get in touch

ECS07 – PRES LTD

Customised keratorefractive surface or lenticule extraction procedure using specialised molded material prior to femtosecond laser incision(s)

Our company is developing a novel approach to corneal refractive surgery designed to overcome key limitations of existing laser-based procedures such as LASIK, PRK, and KLEX. While these techniques have significantly improved visual outcomes, they remain limited in their ability to fully correct corneal irregularities and higher-order aberrations, especially in complex or abnormal corneas.

Our proprietary technology enables customised keratorefractive surface or lenticule extraction procedures without requiring modifications to femtosecond laser platforms or specialised software. The innovation involves applying a biocompatible material to the corneal surface prior to laser docking. This material is molded and polymerised to create a perfectly smooth anterior corneal curvature that serves as a reference surface for the first laser incision.

By temporarily masking corneal irregularities, the method enables the creation of a spherical interface during the initial lamellar cut. Following removal of the molded material, surface extraction procedures eliminate anterior corneal irregularities, leaving a smooth spherical surface that corrects refractive error. In lenticule extraction procedures, a second planar incision captures and corrects native corneal irregularities. The resulting lenticule has adual-surface functionality: one surface optimised for spherical refractive correction and the other tailored to correct complex optical distortions.

This approach replicates the optical quality of rigid contact lenses, enabling a level of precision and regularity not possible with current refractive procedures. It also simplifies the surgical workflow by relying on one or two planar laser incisions and removes dependence on imperfect wavefront or topography-guided measurements.

Our objectives are to improve visual quality by reducing higher-order aberrations and enhancing contrast sensitivity, particularly in low-light conditions; expand the treatable patient population to include irregular corneas and higher refractive errors; and reduce variability and the learning curve associated with existing procedures through a more predictable and reproducible technique. Compatibility with current laser systems lowers adoption barriers and supports rapid integration into clinical practices.

With a validated proof of concept ex vivo and ongoing process optimisation, the company is advancing toward clinical development and regulatory approval. Our long-term vision is to establish this technology as a new standard of care in refractive surgery, capturing a meaningful share of a growing global market while delivering optimised outcomes for patients worldwide.

Company website: www.pres-ltd.com

Supporting documents

Get in touch

ECS08 – RevitalVision

Improving Vision Beyond the Eyes with Patient-Specific Visual Stimulation

About our company:

RevitalVision is a SaaS-based digital health startup headquartered in Israel at an initial growth stage.

We offer a unique solution to millions with poor or insufficient vision whose needs are unmet by existing vision treatments. Our non-invasive technology enhances eyesight neurologically. We utilize brain science and proprietary algorithms to visually stimulate the brain’s visual cortex to improve vision. Our technology has been clinically validated to enhance vision outcomes with long-lasting results in several eye diseases and vision conditions, with a significant impact on vision and quality of life, with an average vision improvement of more than 2 ETDRS lines and 100% improvement in contrast sensitivity. Our product — a home-based vision training app — operates directly from a standard web browser on any personal computer, without the need for any special hardware. Our customers include: 1) Eyecare professionals (B2B) who prescribe the home-based treatment with our software for specific conditions such as amblyopia (lazy eye) and for patients with eye diseases, and 2) Consumers (B2C) seeking wellness and post-surgery solutions beyond available treatments.

Our technology is the only FDA-cleared product with an efficacy claim to improve vision in amblyopia (lazy eye) in patients aged 9 or older and is CE marked with a broad intent for use — to improve vision above age 9.

In 2025, RevitalVision demonstrated efficacy and safety in seven randomized controlled clinical studies, three of which were published in leading peer-reviewed ophthalmology journals (AJO, BJO, and LAJO). The studies investigated RevitalVision efficacy in the following indications: Keratoconus, nystagmus, and post-cataract surgery with multifocal IOL’s and the long-term efficacy (5 years) on adults with amblyopia.

Company website: www.revitalvision.com

Supporting documents

Get in touch

ECS09 – Epion Therapeutics

Vision Ahead of the Curve: EpiSmart Epi-on CXL for Keratoconus

Epion is a late-stage (Phase 3) biotech company developing a non-invasive treatment for keratoconus, a progressive corneal disease that can cause vision loss and blindness.

Epion’s new therapy, the EpiSmart™ Epithelium-On Cross-Linking System, is a non-invasive drug-device combination designed to replace current, highly invasive therapies for keratoconus. EpiSmart is designed to treat keratoconus across a wide spectrum of disease severity, including on diagnosis, through simultaneous bilateral, non-invasive treatment. With an epithelium-on approach without chemical or physical disruption of the epithelium, EpiSmart may significantly reduce patient discomfort and recovery time, allowing for rapid return to daily activities and increasing access to vision-preserving care for millions of patients globally.

Funded by the AXA Global Health Fund and over 50 cornea specialists, Epion completed enrollment in its Phase 3 trials in April 2025 and expects to have results from its Phase 3 trial by August 2026. Epion is currently seeking investment in its Series B venture capital-priced round to accelerate FDA filing and prepare for commercialization.

The safety and efficacy of EpiSmart was investigated in a recently concluded 2,258-subject Phase 2 trial. Results of Epion recent Phase 2 trial, the largest study to-date of corneal cross-linking as a treatment for keratoconus, indicate improvements in visual acuity after EpiSmart treatment at levels similar to currently available treatments, but with a substantial enhancement in safety and comfort compared to the current standard of care.

Company website: www.epiontx.com

Supporting documents

Get in touch

ECS10 – 2EYESVISION

Experience Vision Before Cataract and Presbyopia Surgery

2EyesVision is a Madrid-based ophthalmic technology company developing and commercializing SimVis Gekko2, a wearable, programmable visual simulator that lets patients experience in real time how different intraocular lenses could affect their vision before cataract or presbyopia surgery. Unlike screen-based or purely illustrative tools, SimVis Gekko2 provides a real-world binocular visual experience, helping surgeons and patients make more informed and personalized decisions in a setting where lens choice is otherwise irreversible and often based on explanation rather than direct experience.

The company’s goal is to improve preoperative decision-making, increase patient satisfaction, support adoption of premium IOL procedures, and establish a new standard of care in cataract and presbyopia surgery. The technology is built on proprietary CSIC-originated know-how, has been validated in more than 500 patients with 10,000+ simulations and 10+ clinical trials, and is backed by 30+ scientific publications and 5 patent families.

Company website: www.2eyesvision.com

Supporting documents

Get in touch

ECS11 – Thondar

Refraction Topography: A New Dimension for Myopia Assessment and Clinical Decision-Making Through Retinal Defocus Mapping

Refraction topography (RT) is a novel peripheral refraction measurement tool that can acquire peripheral refraction data across a 53° field of view using rapid focal scanning techniques.

RT develops a refraction algorithm on fundus images at various focusing statuses. Unlike conventional techniques for peripheral refraction measurement, RT requires the subject to stare at a stationary fixation target. The refraction algorithm calculates the focus measure for multiple images at the Point of Interest and formulates them into a focus profile. Its accuracy and repeatability have been recently validated in model eyes, adults, and children. RT makes RPRE visible and measurable, enabling earlier and more precise myopia management, as well as personalized treatment strategies.

Based on clinical application experience in the Chinese market, the use of Refraction Topography can be broadly categorized into four key areas:

1. Early Myopia Risk Assessment

By analyzing defocus patterns beyond 30° eccentricity and in the temporal retina, early changes associated with axial elongation can be identified, enabling prediction of myopia progression.

2. Orthokeratology Lens Fitting Evaluation

By capturing images at the central, nasal, and temporal regions and reconstructing up to a 150° retinal profile, clinicians can assess the area, size, and position of myopic defocus. This allows earlier evaluation of treatment efficacy before detectable changes in axial length.

3. Personalized Lens Design

Based on individual retinal defocus profiles, customized freeform designs on the posterior surface of lenses can be applied to compensate and optimize defocus distribution, improving the effectiveness of myopia control.

4. New Insights for Refractive Surgery

Provides a new analytical dimension for preoperative examination; introducing peripheral defocus data can be used to adjust surgical strategies, increase myopic defocus design, help reduce postoperative regression, and improve surgical outcomes.

Company website: www.thondar.com

Supporting documents

Get in touch

ECS12 – EYE PCR BV

Novel open bag endocapsular device fixOflex – Moving forward to market commercialization and expansion of indications of use

EYE PCR BV is an ophthalmic medical technology company focused on advancing natural human lens replacement surgery through an innovative endocapsular device platform. Its flagship product, fixOflex, is a recently CE-marked implantable device designed to preserve the 3-dimensional shape and intracapsular volume of the capsular bag following lens replacement surgery. Unlike conventional cataract surgery, where the capsular bag progressively contracts after surgery, fixOflex mechanically stabilizes the capsule and creates a more physiological environment for intraocular lens (IOL) positioning and long-term performance.

The device is intended to address several unmet needs in modern lens replacement surgery. By maintaining capsular integrity and stability, fixOflex aims to reduce postoperative capsular contraction and fibrosis, thereby improving posterior capsule opacification (PCO) prevention, IOL centration and rotational stability, and refractive predictability. The device is also designed to support future IOL exchange or repositioning by preserving intracapsular space and surgical access over time.

The technology platform was developed through more than 15 years of translational research and clinical investigation. A recent published peer-reviewed clinical study demonstrated encouraging safety and efficacy outcomes, including reduced PCO incidence for at least 12 months. Based on these clinical findings, fixOflex recently received CE mark approval with indications for preserving capsular form and intracapsular space while reducing PCO for at least 12 months following surgery.

The company’s current objective is to expand the clinical evidence base and broaden the technology’s potential indications. Ongoing clinical studies are evaluating the long-term effects of fixOflex on PCO prevention, its application in premium IOL procedures, and its potential role in pediatric ophthalmology. Additional benchmark and laboratory investigations are further characterizing the biomechanical effects of the device on capsular bag anatomy and stability.

EYE PCR BV is also initiating a soft commercial launch in selected target markets, with broader expansion planned as manufacturing capacity scales. The technology is particularly relevant for the growing premium IOL market, where PCO prevention, lens positioning accuracy, and long-term stability are critical for optimal visual outcomes and patient satisfaction.

The company’s broader vision is to redefine the role of the capsular bag in lens surgery by transforming it from a passive postoperative structure into a stable and durable platform for premium optics and future intraocular therapies.

Through fixOflex, the company aims to establish a new standard in cataract and refractive lens surgery focused on long-term anatomical preservation, optical stability, surgical flexibility, and lifelong patient benefit.

Company website: www.eyepcr.com

Supporting documents

Get in touch

ECS13 – PairedFocus

A New Non-Diffractive Approach to Obtain Near Vision in Presbyopia-Correcting Intraocular Lenses

Background / Unmet Need: Presbyopia-correcting intraocular lenses (IOLs) continue to require a compromise between near visual performance and overall optical quality. While extended depth of focus (EDOF) IOLs provide excellent distance and intermediate vision with reduced photic phenomena, near visual acuity often remains suboptimal. Conversely, trifocal IOLs improve near vision but are frequently associated with dysphotopsia and reduced contrast sensitivity. This ongoing trade-off highlights the need for alternative optical strategies that enhance near vision without sacrificing visual quality.

Innovation: PairedFocus represents a novel, non-diffractive, wavefront-shaping IOL concept designed to extend functional vision into the near range while preserving distance optical performance. Unlike conventional EDOF or diffractive multifocal designs, this approach redistributes optical energy to optimize near vision without introducing diffractive steps, potentially reducing the risk of photic phenomena.

Scientific Rationale and Early Evidence: Preclinical optical bench testing was conducted in accordance with ISO standards to assess through-focus modulation transfer function and simulated visual performance. The near-optimized design demonstrated preserved distance optical quality together with enhanced performance at vergences beyond +2.50 D, resulting in a dual-peak defocus profile. Both alone or combined binocularly with a companion non-diffractive EDOF IOL, the system produced a continuous defocus curve with predicted functional visual acuity across the full range from distance to near. These findings support a complementary binocular strategy, referred to as the Balanced Extended Vision Procedure (BEVPx).

Clinical Relevance and Development Status: This non-diffractive concept aims to bridge the gap between EDOF and trifocal IOLs, offering the potential for improved near vision while maintaining visual quality and minimizing optical side effects. Early clinical experience with this technology is currently being evaluated, with clinical data scheduled for presentation during the ESCRS Congress.

Conclusion: PairedFocus introduces a new optical approach to presbyopia correction that may represent an emerging category of non-diffractive IOLs. By addressing an important unmet clinical need, this technology has the potential to expand the current spectrum of presbyopia-correcting solutions available to cataract and refractive surgeons.

Company website: www.astvc.com

Supporting documents

Get in touch

ECS14 – ViaLase

FLIGHT: A Novel, Non-Surgical, Image-Guided Femtosecond Laser Approach to Trabeculotomy for Glaucoma

ViaLase is developing a femtosecond laser platform designed specifically for glaucoma treatment. The FLIGHT procedure (Femtosecond Laser Image-Guided High-Precision Trabeculotomy) uses high-resolution OCT imaging and ultrafast laser pulses to create precise trabeculotomy channels through the cornea without incisions or implants.

The company is led by pioneers in femtosecond laser technology whose earlier work helped establish ultrafast lasers as a transformative platform for ophthalmic surgery.

The objective of this presentation is to introduce the technology and its underlying mechanism, review the clinical rationale for a non-incisional trabeculotomy approach, and discuss early clinical experience and potential implications for the future management of glaucoma.

Company website: www.vialase.com

Supporting documents

Get in touch

ECS15 – Ophthalmic Therapeutic Innovation

Transform Glaucoma Patient Care via Matrix Metalloproteinase (MMP) pathway Based Therapy

Ophthalmic Therapeutic Innovation, Inc is a clinical stage biotech that develops a breakthrough therapy for treating glaucomatous neural degeneration via matrix metalloproteinase (MMP) pathway activation and tissue rejuvenation. OTI was founded in 2022 by Dr Tina Guanting Qiu, a retinal surgeon and stem cell biologist with decades of drug development experience in industry (GSK, Inotek Pharma, Astellas Pharma). Dr Qiu pioneers big data for IP and regulatory innovation, and made a breakthrough discovery of what causes glaucoma: the pressure sensing cell loss and sensor functional damage (irregularities) is the rate limiting root cause of vision loss in glaucoma. The company is at Seed stage financing with a late stage clinical asset, raised 250,000 pre-seed fund from glaucoma surgeons and physician, no debt, no upfront royalties, 100% ownership of the drug patent and proprietary big data assets. Clean cap table, C Corp ready for institutional financing and partnership.

Lead program: OTI-2024 is the first in class and best in class adenosine A1 receptor agonist, it is a small molecule eye drops, patent protected @ pre-phase 3 stage, backed by 800 patient safety and robust Phase 2 efficacy data, What sets it apart from current eye drops is its derived MMP therapeutic leading to a disease free intraocular pressure (IOP) drug holiday with dosing flexibility. If approved, OTI-2024 will be the first and only glaucoma eye drops that does not require to dose on time.

Market Competitiveness: OTI-2024 is anticipated to replace current prostaglandin glaucoma drug dominance in the past 30 years as the first line therapy.
Patent Portfolio: company holds series of provisional patents and two PCTs which have entered national phase with 6-7 jurisdictions (US, EU, JP, AU, CA, China and India). OTI’s patent portfolio protects the use of Trabodenoson and other MMP-modulating agents for treating glaucoma, with dual mechanisms of action:
– IOP normalization via pressure sensor rejuvenation
– Retinal ganglion cell (RGC) protection via ECM/MMP-driven IOP normalization.

Milestones & Budgets &Timelines:

I) IND clearance: $5.0 millions, 12 months to complete reformulation & CMC for IND clearance and Ph3 enablement.

Ii) Phase 3 pivotal trial: $25MM, 20 months to complete the 6-month IOP normalization study, anticipated on high success
Impact: OTI  is setting new standard of IOP normalization via pressure sensor/sensing cell rejuvenation for glaucoma, redefining glaucoma patient care in decades to come. With MMP pathway based therapy, estimated of majorities of glaucoma patients could potentially achieve a disease free IOP drug holiday with long-term IOP control and visual field stability.

Company website: http://ophthalmic-innovation.com

Supporting documents

Get in touch

ECS16 – Kyara Medical

Active Aqueous Humor Drainage Device. A Smart Bifurcated Shunt Utilizing Closed-Loop MEMS Pumping and Anti-Fibrotic Zwitterionic material for Precise, Standalone Regulation of Refractory Glaucoma, Neutralizing IOP Spikes and Eliminating Chronic Patient Reliance on Pharmaceutical Eye Drops.

Kyara Medical is pioneering a next-generation active-passive intraocular pressure (IOP) regulation system designed to resolve the high failure rates and physiological inflexibility of traditional glaucoma shunts. Our technology utilizes a unique bifurcated architecture: a passive conduit engineered with mathematically defined resistance to maintain a safe drainage floor and prevent early postoperative hypotony, and an active conduit governed by a closed-loop MEMS piezoelectric micropump.
This sensor-driven mechanism activates strictly between 12-18 mmHg to dynamically neutralize nocturnal and postural pressure spikes that passive devices cannot address. To achieve indefinite patency, the device incorporates zwitterionic ultra-high hydrophilic biomaterials that generate a hydration shell to resist protein adsorption. This effectively mitigates the foreign body response and subsequent fibrosis without the surgical use of toxic antimetabolites.

Our primary outcome goals are to deliver a standalone surgical cure that eliminates chronic patient dependency on pharmaceutical eye drops, prevents ischemic optic nerve damage from circadian fluctuations, and fundamentally improves long-term clinical success for refractory glaucoma.

Company website: kyaramedical.com

Supporting documents

Get in touch